On the Record · Halozyme Therapeutics
Halozyme Therapeutics acquisitions, on the record
The businesses Halozyme Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Antares Pharma, Inc.Word for word“On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. (“Antares”) according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the “Merger Agreement”).” 10-K for 2023 | acquisition | On May 24, 2022 | — |
Surf Bio, Inc.Word for word“In December 2025, we completed the acquisition of Surf Bio, Inc., subsequently renamed Halozyme Surf Bio, Inc., resulting in an expansion of our drug delivery technology portfolio and the potential for future growth through new collaboration agreements.” 10-K for 2025 | acquisition | In December 2025 | — |
Elektrofi, Inc.Word for word“As disclosed in Note 3 of the consolidated financial statements, the Company completed the acquisition of Elektrofi, Inc. (“Elektrofi”) on November 18, 2025, for total consideration of $810.4 million.” 10-K for 2025 | acquisition | November 18, 2025 | $810.4 million |
AntaresWord for word“For example, we acquired Antares (in May 2022), Elektrofi (in November 2025), and Surf Bio (in December 2025), as a means to grow and diversify the sources of our revenues.” 10-K for 2025 | acquisition | in May 2022 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2020-12-31 | $0 | — |
| 2021-12-31 | $0 | — |
| 2022-12-31 | $999.1 million | $409 million |
| 2023-12-31 | $0 | — |
| 2024-12-31 | $0 | — |
| 2025-12-31 | $726 million | $163.5 million |
Deal filings since 2016
- 2026-09-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-11-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-11-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-10-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-24 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2022-04-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-03-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-12-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-11-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-05-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-01-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Halozyme Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.